DIRS.INFO The most relevant business & tech news

☆ Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7
▼ + stars: | 2024-03-08 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +7 min

In today's big story, we're looking at pharma companies' surging stocks and threatening tech darlings thanks to their weight-loss drugs. And it comes despite only 1% of US adults taking weight-loss drugs, according to Bank of America , which predicts that number could rise to 15% by 2035. Weight-loss drugs are also cutting more than just fat. For Wall Street, meanwhile, the equation is much simpler: Getting more people on weight-loss drugs boosts the economy. The trend, which will be powered by cash-rich mega-cap tech companies, is thanks to strong earnings growth, the bank said.

Persons: —, Joe Biden, Donald Trump —, Trump, Zhan, Eli Lilly, Tesla, Hannah Latham, Octavio Jones, Christian Rodriguez, Laura MacPherson, Jenny Chang, Rodriguez, they're, Goldman Sachs, Biden, Barry Sternlicht, Fernando Gutierrez, It's, Elon Musk, TikTok, Pete Ryan, RJ Scaringe, Dan DeFrancesco, Hallam Bullock, Jordan Parker Erb, George Glover Organizations: Service, pharma, Business, Tesla, Microsoft, JPMorgan, Pfizer, Novo Nordisk, Bank of America, Nvidia, Companies, Fed, Infrastructure Investment, Alpha, Commission, Elon, EV, Nike, Congress, White, Meta, SXSW Locations: China, US, New York, London

President Joe Biden's State of the Union address as prepared for delivery:Good evening. A former American president actually said that, bowing down to a Russian leader. And it’s because of you that tonight we can proudly say the State of our Union is strong and getting stronger. Americans pay more for prescription drugs than anywhere else. I say this as a lifelong supporter of Israel and the only American president to visit Israel in wartime.

Persons: Joe Biden's, Franklin Roosevelt, “, Hitler, Roosevelt’s, Lincoln, Putin, Ronald Reagan, thundered, Mr, Gorbachev, we’ve, Insurrectionists, ., Jan, I’ve, Latorya Beasley, Roe, Wade, Harris, Kate Cox, Kate, – that's, won’t, Hope, Shawn Fain, Dawn Simms, Dawn, That’s, Jill, I’m, Keenan Jones –, Sen, Bob Casey’s, It’s, It’d, Edmund Pettus, John Lewis, Betty May Fikes, ”, Banning, Jasmine, Jackie, we’re, Evan, Paul, Israel, –, We’ve, aren’t, They’ve, We’re, King, Bobby Kennedy, you’ve, Let’s Organizations: Madame, Union, Overseas, Republican, NATO, Alliance, National Security, America, That's, Act, Infrastructure Law, UAW, Big Pharma, Medicare, Affordable, White, Initiative, Women’s Health Research, Grants, Child, Big Oil, Social Security, Border Patrol Union, Dreamers, Peace Corps, Ameri Corps, Corps, American, House, NRA, Hamas, United, U.S, ARPA, Star Locations: Joe Biden's State, Europe, Russia, Ukraine, American, Russian, America, Finland, Sweden, United States, Birmingham , Alabama, Alabama, Dallas, Texas, COVID, That's America, Belvidere , Illinois, Belvidere, it’s, Shawn, HBCUs, Minnesota, Ireland, Selma , Alabama, Selma, Uvalde , Texas, Uvalde, Iowa, Israel, Gaza, U.S, Saudi Arabia, Iran, Red, China, Taiwan Strait, I’ve, Scranton , Pennsylvania, Claymont , Delaware, United States of America

☆ Analysts love these value stocks, giving 4 more than 30% upside
▼ + stars: | 2024-03-07 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Growth stocks have often been investor darlings — the S & P 500 is driven by stocks in sectors like tech. Value stocks are less popular. But many growth stocks are also becoming expensive, prompting some investors to turn to value stocks. Goldman Sachs also recently highlighted value stocks that stand out for their cheap valuations compared with earnings growth prospects. Those interested in value stocks can consider the following from CNBC Pro's screen of the Vanguard Value ETF.

Persons: darlings, Brian Szytel, Szytel, Goldman Sachs, Baker Hughes, Properties Organizations: Group, CNBC, Vanguard, AES Corporation, Halliburton Company, AES, Royalty Pharma

☆ We're in a 'boomer renaissance,' top hedge fund manager says — naming sectors and stocks to play it
▼ + stars: | 2024-03-05 | by ( Weizhen Tan | ) www.cnbc.com time to read: +1 min

Top hedge fund manager David Neuhauser says the world is in a "boomer renaissance" and investors should be betting big on certain sectors that play the theme. "They are the one demographic which owns the most assets (homes, stocks, bonds, etc) with low fixed rate mortgages," Neuhauser said. He told CNBC Pro, "I think the world is in this boomer renaissance now and there are some stocks that are seeing great moves." He added that the stocks "are not mega tech which shows you other areas tied to the wealth [effect] are helping broadening out gains." Below are the stocks he named and the buy ratings and average upside given by analysts covering them, according to FactSet.

Persons: David Neuhauser, Neuhauser, CNBC's Organizations: Livermore Partners, Big Pharma, CNBC

Even as countries around the world have stepped in to require lower priced drugs for their citizens, the United States has been reticent to do so. As a result, U.S. consumers pay the highest prices in the world for drugs, by a wide margin. But the impetus for more fundamental reform may come from an unexpected place: America’s obesity epidemic. Many of us are aware that there is a new class of weight-loss drugs that offer enormous promise in addressing obesity. But there is far less awareness of the fact that these drugs also introduce an enormous risk to America’s taxpayers.

Organizations: pharma, Novo Nordisk, Ozempic Locations: United States, U.S, Danish

☆ Jim Cramer says he really wants 'everyone to own' this nimble oil and energy stock
▼ + stars: | 2024-03-04 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said the stock is a must-own tied to energy and oil. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Dow, Eaton, Locker, Jerome Powell, Jim, Thomas Jorden, Eli Lilly, Lilly, Jim Cramer's Organizations: CNBC, Nasdaq, Nvidia, Broadcom, Costco, Capitol, Coterra Energy, Management, Wall, UBS, Club, Therapeutics Locations: AVGO, FL

☆ Here are JPMorgan's favorite stocks heading into March
▼ + stars: | 2024-03-04 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

JPMorgan added three new stocks into its list of top stocks heading into March, including two real estate investment trusts. The bank updated its focus list in a Friday note to include Annaly Capital , Ascendis Pharma and EPR Properties . His $20 price target implies that shares could rise nearly 4% from their Friday close. Here are some of the other top picks that made JPMorgan's list: Returning names to the list include growth stock Danaher , which is up nearly 11% this year. Analyst Tami Zakaria's $385 price target implies shares could rise more than 14% from Friday's close.

Persons: Richard Shane, Anthony Paolone, Jessica Fye, Rachel Vatnsdal's, Tami Zakaria's Organizations: JPMorgan, Annaly, Ascendis Pharma, Caterpillar Locations: Friday's

☆ Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
▼ + stars: | 2024-03-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

In this article VKTX Follow your favorite stocks CREATE FREE ACCOUNTCr | Istock | Getty ImagesBiotech company Viking Therapeutics has emerged as a strong potential entrant — or takeover target — in the budding weight loss drug market. Their treatments sparked the weight loss drug industry gold rush over the past year despite their hefty price tags and barriers to insurance coverage. It's too early to say whether Viking's drug could have an edge over existing or developing weight loss treatments. The pharmaceutical giant could also launch a slate of other weight loss treatments over the next few years that may have advantages over Zepbound, whether they offer more weight loss or convenience. That could give Viking the commercial and manufacturing capabilities needed to compete in the weight loss drug market.

Persons: Eli Lilly, Eli Lilly's Zepbound, Viking, Goldman Sachs, Eli Lilly’s, Brendan Mcdermid, GLP, Brian Lian, William Blair, Andy Hsieh, Hsieh, Eli Lilly's, Jefferies, Akash Tewari, doesn't, Mike Segar, Lian, William Blair's Hsieh, Oppenheimer, Jay Olson Organizations: Getty Images Biotech, Viking Therapeutics, Novo Nordisk, Reuters, Viking, Novo, U.S . Food, Drug Administration, Company, Deutsche Bank, CNBC Locations: New York City, Branchburg , New Jersey

☆ Zealand Pharma CEO: Magnitude of obesity pandemic requires many more solutions
▼ + stars: | 2024-03-01 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand Pharma CEO: Magnitude of obesity pandemic requires many more solutionsAdam Steensberg, Zealand Pharma CEO, joins 'Money Movers' to discuss the goal for the company's weight loss drugs, the company's drug around liver disease, and more.

Persons: Adam Steensberg Organizations: Zealand Pharma

☆ CNBC Daily Open: Markets brace for Fed's key inflation gauge
▼ + stars: | 2024-02-29 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

A trader works during the closing bell at the New York Stock Exchange (NYSE) on March 17, 2020 at Wall Street in New York City. This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Overnight, Wall Street ended lower as the 30-stock Dow slipped 0.06% and fell for a third consecutive session. Water scarcity threatens chip makersWater shortages could threaten semiconductor firms such as Taiwan Semiconductor Manufacturing Company, S&P Global Ratings said in a report.

Persons: Dow, Sundar Pichai, Pichai, Ziyu Shen, Eli Lilly, Freddie Lait, Lait Organizations: New York Stock Exchange, Wall, CNBC, CSI, Nikkei, Nasdaq, Google, Taiwan Semiconductor Manufacturing, Nvidia Geely, Nvidia, Novo Nordisk, McKesson Locations: New York City, Asia, U.S

☆ CNBC Daily Open: Wall Street on edge over Fed's key inflation gauge
▼ + stars: | 2024-02-29 | by ( Sumathi Bala | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Markets declineWall Street ended lower Wednesday as investors anxiously wait for the personal consumer expenditures reading for January due today. [PRO] A lesser-known pharma standoutInvestors have been piling into major weight-loss drug manufacturers like Eli Lilly and Novo Nordisk. But fund manager Freddie Lait picked a lesser-known firm that also stands out: McKesson Corp — the U.S. pharmaceuticals distribution company.

Persons: Jerome Powell, Dow, Sundar Pichai, Pichai, Tim Cook, Cook, Walt Disney, Mukesh Ambani, Eli Lilly, Freddie Lait, Lait Organizations: Federal Reserve, New York Stock Exchange, CNBC, Nasdaq, Google, Apple, Walt, Reliance, Asia's, JV, Novo Nordisk, McKesson Locations: New York City, U.S, India

☆ 'Exciting idea': Fund manager loves this pharma stock — and analysts see more upside ahead
▼ + stars: | 2024-02-29 | by ( Amala Balakrishner | In Amala-Balakrishner | ) www.cnbc.com time to read: +3 min

But one firm in the wider ecosystem that's perhaps lesser known stands out to fund manager Freddie Lait, which is McKesson Corp — the U.S. pharmaceuticals distribution company. Calling the company an "exciting idea," Lait noted that the 100-year-old business is "very defensive and very diversified." Lait manages over $750 million collectively between two funds — the Latitude Horizon Fund and the Latitude Global Fund . Of the 19 analysts covering the stock, 14 give it a buy or overweight rating, while three have hold ratings and one has a sell rating. The average price target on the stock is $550.25, according to FactSet data, giving it potential upside of 6%.

Persons: Eli Lilly, Freddie Lait, Lait, —, That's, … It's, McKesson, MCK, — CNBC's Michael Bloom Organizations: Novo Nordisk, Latitude Investment Management, CNBC, U.S, Cardinal Health, McKesson Corp, JPMorgan, Rite Aid, receivables, Leerink Partners, pharma

☆ Stocks making biggest premarket moves: BYND, BMBL, AAP, BIDU and more
▼ + stars: | 2024-02-28 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Check out the companies making the biggest moves in premarket trading: Beyond Meat — Shares soared 59% one day after the plant-based meat company topped fourth-quarter revenue estimates and said it would "steeply reduce" costs this year. EBay — The online marketplace advanced 5% one day it beat fourth-quarter earnings and revenue estimates . In addition, Ebay announced a dividend increase and authorized another $2 billion share buyback. Full-year revenue guidance of $505 million to $510 million was below the $520.9 million consensus estimate. Urban Outfitters — Shares tumbled nearly 10% one day after the clothing retailer's fourth quarter earnings and revenue missed estimates.

Persons: LSEG ., —, Bumble, FactSet ., EBITDA, FactSet's StreetAccount, LSEG, FactSet, TJ, TJX, Sarah Min, Lisa Han, Jesse Pound, Pia Singh, Samantha Subin Organizations: Revenue, Advance, AAP, FactSet, EBay, Ebay, Baidu, SEC, Materials, pharma, Wall, TJX, Marshalls Locations: China, FactSet

☆ Thinking about taking new weight loss drugs? These are the big health risk decisions that will follow
▼ + stars: | 2024-02-28 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +6 min

In this article NOVO.B-DKLLYWWGWW Follow your favorite stocks CREATE FREE ACCOUNTAn injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. But will Americans trust the most iconic brand in the legacy weight-loss business to guide them into its future? "Big pharma was coming for weight loss, and if they didn't have a clinical angle, they would have run the risk of becoming an irrelevant company." "This is a new, incredibly powerful and effective class of pharmaceuticals that a lot of people will find help improve their health." watch nowRisks of overreliance on obesity drugs The risk is real that providers may use the medications and "forget about lifestyle," said John Batsis, an associate professor and nutrition expert at the University of North Carolina Chapel Hill's school of public health.

Persons: Eli Lilly’s, Brendan Mcdermid, Eli Lilly, —, Sima Sistani —, Sistani, Alex Fuhrman, Hallum, Fuhrman, Davidson, Linda Bolton Weiser, I've, Geoff Cook, Cook, John Batsis, Batsis Organizations: Reuters, Novo Nordisk, CNBC, Craig, pharma, University of North, University of North Carolina Chapel Locations: New York City, U.S, Herbalife, University of North Carolina

☆ Popular eye ointments may not be sterile, recall warns
▼ + stars: | 2024-02-28 | by ( Ramishah Maruf | ) edition.cnn.com time to read: +2 min

New York CNN —Eye ointments sold at CVS and Walmart may not actually be sterile, a recall posted by the US Food and Drug Administration warned. On Feb. 26, the FDA posted a voluntary recall from Brassica Pharma, which is recalling several eye ointments with expiration dates ranging from February 2024 to September 2025. This recall is the latest in the FDA’s increased focus on eye products. The agency warned that potential contamination can be a serious health risk because medication applied directly to the eye can “bypass some of the body’s natural defenses.”Brassica’s recall includes brands of eye ointments at popular retailers: Equate Lubricant Eye Ointment (Walmart’s private label), Equate Stye Lubricant Eye Ointment, CVS Health Lubricant Eye Ointment and the Lubricant PM Ointment, which is distributed by AACE Pharmaceuticals. The recall warned customers to stop using the eye ointment and said they can return it.

Persons: ointments, ”, CNN’s Carma Hassan Organizations: New, New York CNN, CVS, Walmart, US Food and Drug Administration, FDA, Pharma, AACE Pharmaceuticals, CNN Locations: New York

☆ Four Eye Ointments Pulled Because of Infection Risk
▼ + stars: | 2024-02-27 | by ( Yan Zhuang | More About Yan Zhuang | ) www.nytimes.com time to read: 1 min

Four eye ointments sold in stores including Walmart and CVS are being recalled because of a potential risk of eye infections or related harm, after U.S. investigators raised concerns about the potential lack of sterility. The voluntary recall involves four over-the-counter products manufactured by Brassica Pharma, according to an announcement by the Food and Drug Administration on Monday. Two are from Equate, a Walmart brand; one is a CVS Health brand; and another is an AACE Pharmaceuticals brand. Brassica Pharma is a drug development and manufacturing company based in the Indian state of Maharashtra that supplies products to the United States, Europe, Asia and Africa, according to the company’s website. Brassica Pharma’s factory is in the city of Tarapur, about three hours north of Mumbai.

Persons: ointments Organizations: Walmart, CVS, U.S, Brassica Pharma, Food and Drug Administration, Pharmaceuticals, Pharma Locations: Indian, Maharashtra, United States, Europe, Asia, Africa, Tarapur, Mumbai

☆ Viking stock doubled Tuesday. Here's where the next moves in the obesity space could come from
▼ + stars: | 2024-02-27 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

VKTX YTD mountain Viking shares year to date Then, Viking shares more than doubled in trading on Tuesday, putting the stock on pace to report a more than 300% year-to-date gain, after the company said its GLP-1/GIP receptor agonist VK2735 hit all its primary goals in a phase 2 clinical trial. The Tema Cardiovascular and Metabolic ETF (HRTS) , which is up 12% year to date, owns Novo, Lilly and Viking. Still early days Some analysts and investors admit it is still very early days for obesity treatment and many questions remain to be answered. "We continue to expect above consensus growth in the space, as we are bullish on adoption from payers and broader obesity uptake," Meacham wrote. For obesity only, Lilly has already gained a 38% share, despite only being in the market for 13 weeks, he said.

Persons: Eli Lilly, Geoff Meacham, Meacham, Lilly, Yuri Khodjamirian, Khodjamirian, Jeff Jonas, Becton Dickinson, Novo, BofA's Meacham, What's, Tema's, it's, Gabelli's Jonas, he's, William Blair, Andy Hsieh, Hsieh Organizations: Novo Nordisk, Bank of America, Centers for Disease Control, Zealand Pharma, Viking Therapeutics, Zealand, Food and Drug Administration, Novo, Metabolic, Therapeutics, Pharmaceuticals, Rock, AstraZeneca, Roche, Gabelli Funds, FDA, Viking, Merck, Pfizer Locations: U.S, Tema, Novo Nordisk's, GLP, Lilly

☆ Here are Tuesday's biggest analyst calls: Nvidia, Arm, Tesla, Rivian, Netflix, Micron, Roku, Seagate & more
▼ + stars: | 2024-02-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Citi reiterates Snowflake as a top pick Citi said Snowflake remains a top pick at the firm. Citi reiterates Micron as buy Citi said concerns about the stock underperformance is overdone and investors should buy the dip in top pick Micron. "We reiterate our Buy rating on Micron and maintain our price target of $95.00, above its historical average given the DRAM upturn and continued upside." "We are initiating coverage of Duolingo with a Buy rating and $222 price target (12x 2025 revenues)." Citi reiterates Nvidia as a top pick Citi said it's staying long shares of Nvidia.

Persons: Morgan Stanley, Rivian, Snowflake, Berenberg, Eli Lilly, Unilever, Edward Jones, Goldman Sachs, Piper Sandler, Piper, Datadog, Yuka Broderick, Janney, Argus, Wells, VZIO, MGY, Bernstein, it's, Evercore, Davidson Organizations: Citi, US pharma, Staples, Fractyl Health, Investor Relations, Strategic Finance, American Eagle Citi, Watch, Micron, UBS, Netflix, SUN, Kroger, Industry, Deutsche Bank, Deutsche, Seaport, Bank of America, Gas, Semiconductors, Nvidia, AMD, Seagate, Bank of, underperform Bank of America, JPMorgan, Comerica, CMA

Berenberg increased its price target on Eli Lilly on the back of expected strong sales of its weight loss drug, Zepbound. The firm kept its $21 price target, saying shares are "ready to inflect" with hardware cost deflation and investment tax credit boosting growth. Danely's $820 price target on the buy-rated blockbuster chipmaker suggests 3.6% potential upside for shares since Monday's close. — Pia Singh 5:38 a.m.: Berenberg hikes Eli Lilly price target Eli Lilly has been on a tear this year, and Berenberg expects even more gains from here. Analyst Kerry Holford reiterated his buy rating on the stock and raised his price target to $850 from $680.

Persons: Berenberg, Eli Lilly, John Hodulik, Hodulik, — Pia Singh, Wells, Steven Cahall, Cahall, ROKU, Fred Imbert, BofA Evercore, James West, Christopher Danely, Danely, Goldman Sachs, Edward Jones, James Shanahan, Goldman, Marcus, Apiro Dounls, Sunoco, Kerry Holford, Holford, Zepbound Organizations: CNBC, pharma, Nvidia, Citi, Sunoco, NuStar Energy, Netflix, UBS, Vizio, CTV, ISI, BofA, BofA Evercore ISI, Bank of America, Micron Technology, NuStar, SUN Locations: Wells, Sunrun, Monday's

☆ This biotech startup wants to prevent unhappiness. Here's the pitch deck Matter Bioscience used to raise $26 million.
▼ + stars: | 2024-02-26 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +4 min

Read previewAxel Bouchon cofounded Matter Neuroscience in 2019 after leading the venture arms of pharma giants Moderna and Bayer. AdvertisementMatter has emerged from stealth with $26 million from ARCH Venture Partners, Polaris Partners, Exor Ventures, and Collaborative Fund, Business Insider has learned exclusively. That $26 million includes an initial seed round led by Polaris Partners and a Series A round led by ARCH Venture Partners. The startup views itself now as a consumer biotech startup, Bouchon said. Here's the 17-slide pitch deck Matter used to raise $26 million.

Persons: —, Axel Bouchon, Bouchon Organizations: Service, pharma, Moderna, Bayer, Business, Venture Partners, Polaris Partners, Exor Ventures, Fund, Brain Imaging, Icahn School of Medicine Locations: Maastricht, Netherlands, Mount Sinai, Seoul, South Korea

☆ Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results
▼ + stars: | 2024-02-26 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials move along a conveyor at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Monday, June 12, 2023. Shares of Denmark's Zealand Pharma rocketed higher, after the company posted strong results from a trial of a liver disease treatment that has been touted as a potential competitor in the booming weight-loss drug market. The drug has "demonstrated efficacy" in people with obesity and is currently undergoing five Phase-3 trials in a clinical program for people who are overweight or obese. Analysts latched onto the drug's possible efficacity in obesity research following the latest test results, which indicated the safety of the top dosage used in that trial. Several other firms, including Eli Lilly, Roche and AstraZeneca, also seek to compete in the sector.

Persons: Ozempic, Eli Lilly, Roche Organizations: Novo Nordisk, pharma, Denmark's Zealand Pharma, U.S . Food, Drug Administration, Zealand Pharma, Nordisk, AstraZeneca Locations: Hillerod, Denmark, U.S, London, Danish

☆ Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailZealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Persons: Eli Lilly, Mizuho's Jared Holz Jared Holz Organizations: Novo Nordisk, Zealand Pharma Locations: Mizuho

☆ Monday rapid fire: Walmart, Berkshire Hathaway, Domino's Pizza and Zealand Pharma
▼ + stars: | 2024-02-26 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMonday rapid fire: Walmart, Berkshire Hathaway, Domino's Pizza and Zealand PharmaDuring the CNBC Investing Club's Morning Meeting on Monday, Jim Cramer discussed four stocks in the news, including Walmart and Warren Buffett's Berkshire Hathaway.

Persons: Berkshire Hathaway, Jim Cramer, Warren Buffett's Berkshire Hathaway Organizations: Walmart, Zealand Pharma, CNBC Locations: Berkshire, Warren

☆ After Walmart's stock split, Jim Cramer says this chipmaker should be next
▼ + stars: | 2024-02-26 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Walmart : The Arkansas-based retail giant's 3-for-1 stock split went into effect Monday, and Jim Cramer said he'd like to see other companies consider taking similar moves. "This is something that [CEO] Doug McMillon said that [founder] Sam Walton liked because people don't like partial stock. I think that companies like Broadcom should be listening to that, and they should be splitting," Cramer said. "They gave you a really long-term view, and it was very positive," Cramer said.

Persons: Jim Cramer's, Jim Cramer, Cramer, Doug McMillon, Sam Walton, Berkshire Hathaway, Warren Buffett's, there's, Buffett, it's, Boehringer Ingelheim, Eli Lilly, — Organizations: CNBC, Club, Walmart, Broadcom, Cramer's Charitable Trust, Berkshire, Zealand Pharma Locations: Arkansas, Cramer's, Arbor , Michigan, Danish

☆ This sector offers defensive and growth properties – along with some portfolio income
▼ + stars: | 2024-02-26 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +6 min

The health-care sector of the S & P 500 is up about 8% year to date, marking a sharp comeback from a largely flat 2023. Even as health care is making a comeback this year, investors shouldn't forget its defensive attributes. Back in 2022, when the S & P 500 fell 19.4%, the health-care sector slipped only 3.5% "When markets are challenged, health care can be a good place to be," Lyons added. Some of them speak to the growth aspects of health care and why you can play offense." Merger activity is another driver of growth in health care, as large pharmaceutical companies snap up nimble biotech firms that are at the forefront of developing treatments.

Persons: Dan Lyons, Janus Henderson, shouldn't, Lyons, ImmunoGen, Seamus Fernandez, Sotatercept, Cigna, Cantor Fitzgerald, Sarah James, Fred Imbert Organizations: Big Tech, . Healthcare, Janus, Janus Henderson Investors, U.S . Food, Drug Administration's Center, Drug, Research, FDA, Esai, Pharmaceuticals, CNBC Pro, Merck, Abbott Laboratories, AbbVie, CVS Health Locations: U.S

Search resuls for: "PHARMA"

25 mentions found